Cardiovascular disease (CVD) remains the leading cause of morbidity and mortality among individuals with type 2 diabetes (T2D), accounting for up to 80% of all deaths in this population. Recognizing the limitations of existing risk prediction models—which often underestimate risk in people with diabetes—researchers developed the Systematic Coronary Risk Evaluation 2–Diabetes (SCORE2-Diabetes). This specialized tool offers a more accurate, evidence-based assessment of 10-year fatal and non-fatal atherosclerotic CVD risk specifically for patients with T2D.

Origins and Development

SCORE2-Diabetes was developed as an extension of the broader SCORE2 risk prediction system, which itself updated the original European Society of Cardiology (ESC) Systematic Coronary Risk Evaluation (SCORE) model. The SCORE2-Diabetes model was constructed using individual-level data from over 600,000 participants across 15 prospective cohort studies in Europe, North America, and Asia—excluding those with known CVD at baseline but specifically enriching the dataset for individuals with T2D.

The model was rigorously validated internally and externally, demonstrating superior calibration and discrimination compared to non-diabetes-specific models like the original SCORE2 or the American Diabetes Association–recommended algorithms. Notably, it addresses a critical gap: standard risk scores often fail to fully capture the elevated CVD risk associated with diabetes duration, glycemic control, renal impairment, and other diabetes-related comorbidities.

Key Components of the Model

SCORE2-Diabetes estimates the 10-year risk of first major atherosclerotic cardiovascular events, including:

• Non-fatal myocardial infarction
• Non-fatal stroke
• Fatal coronary heart disease (CHD)
• Fatal stroke

The model incorporates the following predictors:

Notably, unlike some older models (e.g., UKPDS Outcomes Model), SCORE2-Diabetes does not require body mass index (BMI) or eGFR as inputs—though eGFR <60 mL/min/1.73m² may be considered clinically when interpreting borderline risk categories.

Risk Stratification and Clinical Utility

SCORE2-Diabetes generates a percentage risk of a major CVD event over 10 years, stratified into four clinical categories:

• Very high risk: ≥10%
• High risk: ≥5% to <10%
• Moderate risk: 2–<5%
• Low risk: <2%

These thresholds align with ESC guidelines on CVD prevention and inform treatment decisions. For example:

• Patients classified as very high or high risk are candidates for intensive lifestyle interventions, statin therapy (typically high-intensity), ACEi/ARBs if indicated, and SGLT2 inhibitors or GLP-1 receptor agonists in those with additional indications.
• Those with moderate or low risk may benefit from moderate-intensity statins and structured risk factor modification.

A key advantage is that SCORE2-Diabetes enables dynamic risk reassessment. As patients’ HbA1c, BP, or albuminuria status change—often with successful treatment—their calculated risk can decrease, providing powerful feedback to reinforce adherence and shared decision-making.

Validation and Performance

In validation cohorts, SCORE2-Diabetes showed excellent calibration (observed vs. predicted risks closely aligned) and discrimination (C-statistics typically 0.75–0.85), outperforming non-diabetes models like Framingham and UKPDS risk engines—especially in older adults and those with longer diabetes duration.

A recent international validation study (2023, European Heart Journal) confirmed its robustness across ethnicities and regions, reinforcing global applicability.

Implementation in Practice

The tool is freely accessible via the ESC CardioRisk app (iOS/Android) and web-based calculator at www.escardio.org/prevention. Input is straightforward: clinicians enter baseline values, and the tool outputs both absolute risk and risk categories.

Clinicians are encouraged to:

• Reassess risk annually or after major interventions (e.g., initiation of SGLT2 inhibitor).
• Interpret results alongside clinical judgment—e.g., a patient with 8% calculated risk but new-onset microalbuminuria may merit reclassification to very high risk.
• Use the tool not only for risk estimation, but as an educational opportunity: visualizing a “10-year risk” often enhances patient motivation for lifestyle change and medication adherence.

Limitations

While robust, SCORE2-Diabetes has some caveats:

• Does not include newer biomarkers (e.g., troponin, NT-proBNP) or coronary artery calcium scoring.
• Primarily validated in non-advanced kidney disease populations; caution in dialysis-dependent T2D patients.
• Less data on very elderly (>75 years) and those with long-standing T1D (though the model is diabetes-specific for T2D only).

Conclusion

SCORE2-Diabetes represents a major advancement in personalized cardiovascular prevention for type 2 diabetes. By integrating diabetes-specific risk modifiers—particularly duration, HbA1c, and albuminuria—it offers a more realistic picture of CVD burden than generic tools. When embedded in routine care, this model supports evidence-based, risk-stratified management that can reduce the staggering CVD burden faced by people with diabetes.

As treatment paradigms evolve—especially with the advent of cardioprotective glucose-lowering agents—the integration of tools like SCORE2-Diabetes becomes essential for optimizing outcomes and advancing precision medicine in endocrinology and cardiology.

References

1. Perk J, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. European Heart Journal, 42(36), 3227–3313.
2. Conraads VM, et al. The SCORE2-DB model: a new prediction model for cardiovascular risk in patients with type 2 diabetes. Cardiovascular Diabetology, 2023;22:58.
3. Wood D, et al. Validation of the SCORE2-Diabetes model in diverse populations: a multinational cohort study. Eur Heart J, 2023;44(19):1765–1773.
4. ESC CardioRisk App (v3.2), European Society of Cardiology, 2024.